ibrutinib,venetoclax
janssen,abbvie,roche
['ibru', 'leukemia']
new #imbruvica (ibrutinib) data in fixed-duration combination regimen presented at #eha 2022 shows deep, durable response at three years in untreated chronic lymphocytic leukemia #johnsonandjohnson #lym - 
BioPharma Asia the premier source for unbiased, cutting edge editorial written the leading figures currently working in the global Pharma/Biopharma industry.